STOCK TITAN
  1. Home
  2. Sec-filings
  3. SION
  4. [Form 4] Sionna Therapeutics, Inc. Insider Trading Activity

17,340 Sionna Therapeutics (SION) options granted via OrbiMed-linked agreement

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Sionna Therapeutics director Peter A. Thompson reported a grant of 17,340 non-qualified stock options linked to Sionna Therapeutics, Inc. common stock. The options have an exercise price of $36.73 per share and expire on June 16, 2036. They vest in full on the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., contingent on his continued service. Under an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, any securities or economic benefits from these options are to be transferred so that the economic benefit is provided to OrbiMed Private Investments VIII, LP.

Positive

  • None.

Negative

  • None.
Insider Thompson Peter A.
Role null
Type Security Shares Price Value
Grant/Award Non-Qualified Stock Option (right to buy) 17,340 $0.00 --
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 17,340 shares (Direct, null)
Footnotes (1)
  1. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP. This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.
Options granted 17,340 options Non-qualified stock option grant to director
Exercise price $36.73 per share Exercise price of Sionna Therapeutics options
Expiration date June 16, 2036 Option term end date
Vesting timing Earlier of June 17, 2027 or next annual meeting Full vesting trigger, service-based
Post-transaction derivative holdings 17,340 options Total derivative securities following transaction
Non-Qualified Stock Option (right to buy) financial
"security_title: "Non-Qualified Stock Option (right to buy)""
grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
economic benefit financial
"transfer any securities or the economic benefit thereof to OrbiMed"
OrbiMed Advisors LLC financial
"agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC"
annual meeting financial
"earlier of June 17, 2027 or the date of the next annual meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Thompson Peter A.
(Last)(First)(Middle)
C/O SIONNA THERAPEUTICS, INC.
21 HICKORY DRIVE, SUITE 500
(Street)
WALTHAM MASSACHUSETTS 02451
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Sionna Therapeutics, Inc. [ SION ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)(1)$36.7306/17/2026A17,340 (2)06/16/2036Common Stock17,340$0.017,340D
Explanation of Responses:
1. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.
2. This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.
By: Jennifer Fitzpatrick, Attorney-in-Fact For: Peter Thompson06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Sionna Therapeutics (SION) disclose in this Form 4?

Sionna Therapeutics disclosed a grant of 17,340 non-qualified stock options to director Peter A. Thompson. These options relate to common stock, represent a compensation award, and increase his reported derivative holdings to 17,340 options following the transaction.

What is the exercise price and expiry of the new SION stock options?

The granted SION options have an exercise price of $36.73 per share and an expiration date of June 16, 2036. This means they can be exercised at $36.73 any time after vesting until that expiration date, subject to the award’s terms.

When do the newly granted Sionna Therapeutics (SION) options vest?

The options vest in full on the earlier of June 17, 2027 or the next annual meeting of Sionna Therapeutics, Inc. Vesting is contingent on Peter A. Thompson’s continued service through that vesting date under the award’s conditions.

How many SION derivative securities does the insider hold after this grant?

After the transaction, the Form 4 shows 17,340 derivative securities held, all from this non-qualified stock option grant. There are no additional remaining derivative positions listed in the filing’s derivative position summary section.

What role do OrbiMed entities play in this Sionna Therapeutics (SION) option grant?

Under an agreement, any securities or economic benefits from the options must be transferred so that OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC ensure the economic benefit is provided to OrbiMed Private Investments VIII, LP.

Is this Sionna Therapeutics (SION) Form 4 an open-market purchase or a compensation grant?

The Form 4 reflects a compensation-related option grant, not an open-market share purchase. The transaction code is “A,” described as a grant, award, or other acquisition, with a transaction price per option of $0.00.